Sequana Medical Notice of 2022 Full Year Results and Business Update
02. Februar 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 2 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces grant of additional DSR® patent in United States
01. Februar 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASE Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease,...
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
11. Januar 2023 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION11 January 2023, 07:00 am CEST Ghent, Belgium – 11 January 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in...
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
15. November 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION15 November 2022, 07:00 am CET Data from SAHARA with first-generation DSR product (DSR 1.0) confirm: Safe, effective and rapid elimination of...
Sequana Medical to present at Jefferies London Healthcare Conference
08. November 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease,...
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
25. Oktober 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION25 October 2022, 07:00 am CET alfapump achieves pre-specified primary effectiveness endpoints with statistical significance at six months...
Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®
21. Oktober 2022 01:00 ET
|
Sequana Medical NV
Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC:“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent...
Sequana Medical announces H1 2022 results and provides business update
08. September 2022 01:00 ET
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION8 September 2022, 07:00 CET alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON...
Sequana Medical Notice of 2022 Half Year Results and Business Update
01. September 2022 01:00 ET
|
Sequana Medical NV
Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease,...
Alexandra Clyde appointed to Sequana Medical Board of Directors
25. August 2022 01:00 ET
|
Sequana Medical NV
Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...